[go: up one dir, main page]

WO2003014745A3 - Method for identifying anti-inflammatory drugs - Google Patents

Method for identifying anti-inflammatory drugs Download PDF

Info

Publication number
WO2003014745A3
WO2003014745A3 PCT/EP2002/007937 EP0207937W WO03014745A3 WO 2003014745 A3 WO2003014745 A3 WO 2003014745A3 EP 0207937 W EP0207937 W EP 0207937W WO 03014745 A3 WO03014745 A3 WO 03014745A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory drugs
identifying anti
nhr
identifying
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/007937
Other languages
French (fr)
Other versions
WO2003014745A2 (en
Inventor
Birgit Jung
Norbert Kraut
Stefan Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to AU2002321229A priority Critical patent/AU2002321229A1/en
Priority to JP2003519426A priority patent/JP2005503787A/en
Priority to MXPA04001128A priority patent/MXPA04001128A/en
Priority to EP02754896A priority patent/EP1425587A2/en
Priority to CA002453913A priority patent/CA2453913A1/en
Publication of WO2003014745A2 publication Critical patent/WO2003014745A2/en
Anticipated expiration legal-status Critical
Publication of WO2003014745A3 publication Critical patent/WO2003014745A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to NHR-proteins involved in inflammatory processes and the modulation of the function of such a NHR-protein in order to positively influence inflammatory diseases.
PCT/EP2002/007937 2001-08-06 2002-07-17 Method for identifying anti-inflammatory drugs Ceased WO2003014745A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002321229A AU2002321229A1 (en) 2001-08-06 2002-07-17 Method for identifying anti-inflammatory drugs
JP2003519426A JP2005503787A (en) 2001-08-06 2002-07-17 Methods for identifying substances that positively affect inflammatory symptoms
MXPA04001128A MXPA04001128A (en) 2001-08-06 2002-07-17 Method for identifying substances which positively influence inflammatory conditions.
EP02754896A EP1425587A2 (en) 2001-08-06 2002-07-17 Method for identifying anti-inflammatory drugs
CA002453913A CA2453913A1 (en) 2001-08-06 2002-07-17 Method for identifying substances which positively influence inflammatory conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01119003 2001-08-06
EP01119003.0 2001-08-06

Publications (2)

Publication Number Publication Date
WO2003014745A2 WO2003014745A2 (en) 2003-02-20
WO2003014745A3 true WO2003014745A3 (en) 2004-03-25

Family

ID=8178260

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007937 Ceased WO2003014745A2 (en) 2001-08-06 2002-07-17 Method for identifying anti-inflammatory drugs

Country Status (6)

Country Link
EP (1) EP1425587A2 (en)
JP (1) JP2005503787A (en)
AU (1) AU2002321229A1 (en)
CA (1) CA2453913A1 (en)
MX (1) MXPA04001128A (en)
WO (1) WO2003014745A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074969A2 (en) * 2004-02-07 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024471A1 (en) * 1997-11-10 1999-05-20 The Research Foundation Of State University Of New York Opiate, cannabinoid, and estrogen receptors
WO2000053563A1 (en) * 1999-03-11 2000-09-14 Nuclear Receptor Research Limited Novel ligands of nuclear receptors ppar's
WO2001022988A1 (en) * 1999-09-30 2001-04-05 Aubin Jane E ESTROGEN RELATED RECEPTOR, ERRα, A REGULATOR OF BONE FORMATION
WO2002052270A2 (en) * 2000-12-22 2002-07-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
WO2002052036A2 (en) * 2000-12-22 2002-07-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Identification of modulators of dham-kinase and inflammatory diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024471A1 (en) * 1997-11-10 1999-05-20 The Research Foundation Of State University Of New York Opiate, cannabinoid, and estrogen receptors
WO2000053563A1 (en) * 1999-03-11 2000-09-14 Nuclear Receptor Research Limited Novel ligands of nuclear receptors ppar's
WO2001022988A1 (en) * 1999-09-30 2001-04-05 Aubin Jane E ESTROGEN RELATED RECEPTOR, ERRα, A REGULATOR OF BONE FORMATION
WO2002052270A2 (en) * 2000-12-22 2002-07-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
WO2002052036A2 (en) * 2000-12-22 2002-07-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Identification of modulators of dham-kinase and inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NUCLEAR RECEPTORS NOMENCLATURE COMMITTEE, 1999: "A unified nomenclature system for the nuclear receptor superfamily.", CELL, vol. 97, 16 April 1999 (1999-04-16), pages 161 - 163, XP002267664 *

Also Published As

Publication number Publication date
CA2453913A1 (en) 2003-02-20
MXPA04001128A (en) 2004-05-20
EP1425587A2 (en) 2004-06-09
AU2002321229A1 (en) 2003-02-24
WO2003014745A2 (en) 2003-02-20
JP2005503787A (en) 2005-02-10

Similar Documents

Publication Publication Date Title
AU2002305793A1 (en) Database access bridge system and process
AU2002251612A1 (en) Stent and method for the production thereof (variants)
AU2003274641A1 (en) System and method for the optimization of database
AU2002358270A1 (en) Zero-order sustained released dosage forms and method of making the same
AU2002364528A1 (en) Bio-implant and method of making the same
AU4279000A (en) Bolted metal joist and method of manufacturing the same
AU2001265059A1 (en) Light gauge metal truss system and method
WO2003102012A3 (en) New etonogestrel esters
EP1326306A3 (en) Connecting member for flat circuit member and method of connecting the connecting member and the flat circuit member
AU2002245472A1 (en) An automated bidding process and system
AU2002309083A1 (en) Method for identifying drugs for the treatment of type ii diabetes
CA2418506A1 (en) Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
AU2002253691A1 (en) Lamp and method of manufacturing the same
AU2002364914A1 (en) Computer-implemented system and method for productivity enhancement
AU2002301109A1 (en) Method for the prediction of preeclampsia and other diseases
WO2003014745A3 (en) Method for identifying anti-inflammatory drugs
WO2004016640A3 (en) 5 ANDROSTEN-3β-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
AU2002250831A1 (en) Method for the production of sputtering targets
AU2002308805A1 (en) Magnesium-based alloy and method for the production thereof
WO2002052270A3 (en) Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
WO2003031584A3 (en) Axon repair
AU2001276049A1 (en) Method of enabling the spacing of metal units
AU2001274004A1 (en) Method for the production of 2- coumarone and substituted 2-coumarones
WO2002052269A3 (en) Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
AU2002250813A1 (en) Pesticide and method for the production thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2453913

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002754896

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/001128

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003519426

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002754896

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002754896

Country of ref document: EP